Lonvoguran

Asset

Disrupts KLKB1 in liver cells to reduce plasma kallikrein production.

Stage
Stage not known
Modality
Gene editing
Target
Not known
0
Indications
0
Trials
1
Developer

Named in the news on Oct 29, 2026. news.google.com

Indications

0

    In the full profile

    • Owner and partners1
    • Signals3

    Every asset’s record: target, stage, trials and the evidence behind it.

    See Pro

    Assets